Send us Feedback

Allos Therapeutics (ALTH)
Analysis
SUMMARY
BULLS
BEARS
TOPICS
Data
DATA CENTRAL
STOCK CHART
Financials
SEC FILINGS
BALANCE
INCOME
CASH FLOW
QUOTE AND NEWS
Allos (ALTH) Sees Increased Volatility; FTC Requests More Info on Merger with Spectrum (SPPI)
StreetInsider.com  May 10  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/Allos+%28ALTH%29+Sees+Increased+Volatility%3B+FTC+Requests+More+Info+on+Merger+with+Spectrum+%28SPPI%29/7424069.html for the full story.
Spectrum Pharmaceuticals and Allos Therapeutics Announce Extension of Previously Announced Tender Offer For Shares of Allos Therapeutics
Benzinga  May 10  Comment 
Spectrum Pharmaceuticals, Inc. (Nasdaq: SPPI) and Allos Therapeutics, Inc. (Nasdaq: ALTH) (Allos) today announced that, on May 9, 2012, each had received from the Federal Trade Commission (FTC) a Request for Additional Information and Documentary...
Robbins Geller Rudman & Dowd LLP Files Class Action Suit Against Allos Therapeutics, Inc.
Business Wire  May 1  Comment 
Robbins Geller Rudman & Dowd LLP (“Robbins Geller”) today announced that a class action has been commenced in the United States District Court for the District of Colorado on behalf of all persons who held shares of the common stock of Allos
Spectrum Could Sink In Wake Of Trial Failures
Investment Underground » Page not found  Apr 23  Comment 
by Erica Thinesen Over the past few weeks, Spectrum (SPPI) has received a lot of attention, mostly due to the failure of two clinical trials for its drug aqaziquone, used in the treatment of bladder cancer, and for the recent purchase of Allos...
Allos Therapeutics Announces Outcome of Request for Re-examination of CHMP Opinion for FOLOTYN® in Europe
Business Wire  Apr 20  Comment 
Allos Therapeutics, Inc. (NASDAQ: ALTH) announced today that following its request for re-examination, the European Medicines Agency’s Committee For Medicinal Products for Human Use (CHMP) confirmed its previous negative opinion on the marketing
Allos (ALTH) Says CHMP Reaffirms Negative Opinion on FOLOTYN MAA
StreetInsider.com  Apr 20  Comment 
Spectrum (SPPI) Commences Tender for Allos (ALTH) Common
StreetInsider.com  Apr 16  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/Spectrum+%28SPPI%29+Commences+Tender+for+Allos+%28ALTH%29+Common/7345193.html for the full story.
Spectrum Pharmaceuticals Commences Tender Offer for All Outstanding Shares of Allos Therapeutics at $1.82/Share for Each Allos Stock
Benzinga  Apr 16  Comment 
Spectrum Pharmaceuticals (NASDAQ: SPPI) today announced that it commenced on Friday, April 13, 2012 a cash tender offer to purchase all of the outstanding shares of common stock of Allos Therapeutics, Inc. (NASDAQ: ALTH). The tender offer is being...
UPDATE: Brean Murray Carret Downgrades Allos Therapeutics to Hold
Benzinga  Apr 10  Comment 
Brean Murray Carret lowers its rating on Allos Therapeutics (NASDAQ: ALTH) following a definite acquisition agreement with Spectrum. The price target of $2.50 is discontinued. Brean Murray Carret says, "The boards of directors for both Spectrum...
UPDATE: Brean Murray Carret Downgrades Allos Therapeutics; Removes PT
Benzinga  Apr 9  Comment 
According to a research report published earlier today, Brean Murray Carret has downgraded Allos Therapeutics (NASDAQ: ALTH) from Buy to Hold, and removed its $2.50 PT. In the report, Brean Murray Carret commented, “The boards of directors...
Spectrum Pharma: The Growth Party is Over
TheStreet.com  Apr 9  Comment 
if !IE-->endif-->Content on this page requires a newer version of Adobe Flash Player.if !IE-->endif--> HENDERSON, Nev. (TheStreet) --The Spectrum Pharmaceuticals growth party is over. The bladder cancer drug aqaziquone blew up Thursday...




RELATED WIKI ARTICLES

Related Articles

more ▼WIKI ANALYSIS
 
TOP CONTRIBUTORS
Sr. Director
Grant Zeng
www.zacks.com

Allos Therapeutics Inc. (Allos) is a biopharmaceutical company focused on developing and commercializing small molecule drugs for the treatment of cancer. The company strives to develop proprietary products that have the potential to improve the standard of care in cancer therapy. Allos' goal is to build a profitable company by generating income from products it develops and commercializes, either alone or with one or more potential strategic partners. The company's focus is on product opportunities that leverage its internal clinical development and regulatory expertise and address important markets with unmet medical need. Allos may also seek to grow its existing portfolio of product candidates through product acquisition and in-licensing efforts.

Allos has two product candidates that are currently under clinical development, PDX (pralatrexate) and RH1.

Candidate


Target Indications


Status


PDX:






Chemotherapy


Peripheral T-cell lymphoma


Phase II ongoing




Non-Hodgkin's lymphoma and Hodgkin's disease


Phase I/II ongoing




cutaneous T-cell lymphoma


Phase I/II ongoing




Stage IIIB/IV non small cell lung cancer


Phase I ongoing


RH1:






Chemotherapy


Solid Tumors


Phase I ongoing


Allos Therapeutics was incorporated in 1992 and is headquartered in Westminster, CO.




References

Retrieved from "http://www.wikinvest.com/stock/Allos_Therapeutics_(ALTH)"
Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki